mobilization in rat cardiomyocytes.
endothelin-1; intracellular free calcium; vasopressin THE PRESENCE OF ALL COMPONENTS of the renin-angiotensin system in neonatal rat cardiomyocytes (NRC) is consistent with its role in maintaining cardiovascular homeostasis (3, 5) . Angiotensin II (ANG II) regulates cardiac contractility and growth via stimulation of angiotensin type 1 (AT 1 ) receptors (3) . Stimulation of AT 1 receptors leads to Ca 2ϩ mobilization through the activation of phospholipase C (PLC), resulting in the generation of inositol (1, 4, 5) -trisphosphate [Ins(1,4,5)P 3 ] and diacylglycerol (12, 27, 31, 32) . The mechanisms governing the regulation of ANG II-evoked increases in cystosolic free calcium concentration ([Ca 2ϩ ] i ) levels are not fully understood. Besides enhancing the [Ca 2ϩ ] i level, ANG II elicits complex intracellular signaling events that include the production of superoxide anions and the activation of several kinases as well as the alteration of cyclic nucleotides and nitric oxide levels (31) . In addition, ANG II activates phospholipase A 2 and D, resulting in elevation of arachidonic acid (AA)-derived metabolites (6, 15, 19, 22, 24, 36) . In rat vascular smooth muscle cells, the hypertrophic responses to ANG II are suggested to be at least partially linked to generation of noncyclooxygenase-derived AA metabolites (6, 22) . Recently, we and others have demonstrated that ANG II-evoked vasoconstrictor responses in rat aortic rings and perfused rat mesenteric vascular bed were reduced by 2-[12-hydroxydodeca-5,10-diynyl]-3,5,6-trimethyl-p-benzoquinone (AA-861), a selective blocker of 5 
-lipoxygenase (5-LO), or 3-[[[3-[2-(7-chloro-2-quinlinyl)ethinyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-(E) sodium salt (MK-571)
, a selective cysteinyl leukotriene (CysLT) 1 antagonist (29, 30) . These data suggested that ANG II may enhance the production of the AA-derived 5-LO metabolite CysLT. However, whether ANG II promotes CysLT production in vascular smooth muscle cells and cardiomyocyte has not been investigated. CysLT include leukotriene D 4 (LTD 4 ), C 4 (LTC 4 ), and E 4 (LTE 4 ). They exert their actions via activation of at least two pharmacologically defined G proteincoupled receptors (CysLT 1 and CysLT 2 ) that are linked to PLC-mediated Ca 2ϩ mobilization (8, 16) . In addition to their well-known bronchiolar smooth muscle spasmogenic effect, these inflammatory mediators have been shown to enhance contractile responses in smooth muscle preparations or [Ca 2ϩ ] i levels in their target cells (4, 10, 20, 21, 23, 29, 30) . Recently, with the use of a variety of techniques including in situ hybridization, Northern blotting, and RT-PCR, the presence of CysLT 1 and/or CysLT 2 transcripts in cardiac tissue has been identified (8, 10, 16, 21) . CysLT has been shown to exert potent effects on the heart, contributing to heart failure (2, 10) . Leukotriene A 4 hydrolase plays a critical role in the generation of CysLT, and its expression is elevated in the heart of ANG II-induced hypertensive rats, suggesting that ANG II may promote cardiac CysLT production (9) . Moreover, low concentrations of CysLT, specifically LTD 4 and LTC 4 , have been shown to promote a positive inotropic effect in the rat heart (11) . Despite these reports, there are no studies to demonstrate that CysLT, namely, LTD 4 and LTC 4 , promotes Ca 2ϩ mobilization and that ANG II-evoked Ca 2ϩ mobilization is linked to CysLT generation in cardiomyocytes. In the present study, using adherent NRC in primary cultures, we attempted to address these issues.
MATERIALS AND METHODS
Cardiomyocyte cultures. The care and use of animals conforms to the regulations stipulated by the University Animal Care Committee. The details of isolation and primary culture of ventricular myocytes from newborn (3 days old) SpragueDawley rats have been previously described (14, 34, 35) . After removal of mesenchymal cells, the cell suspension was layered on either six-well culture plates for CysLT assay or on glass coverslips for fluorescence measurement. Bromodeoxyuridine (0.1 mM) was included in the medium to ensure selective suppression of mesenchymal cells to facilitate purified myocyte-rich (Ͼ95%) primary cultures of NRC (14) .
Determination of [Ca 2ϩ ]i using fura 2 fluorescence in adherent NRC. After NRC grown on glass coverslips attained confluence (3 days), the cells were maintained in serum-free medium for 24 h. The cells were washed twice in Krebs-HEPES buffer [composed of (in mM) 145 NaCl, 5 KCl, 1.8 CaCl 2 ⅐ 2H2O, 1.2 MgCl2 ⅐ 6H2O, 10 glucose, and 10 HEPES with 0.2% BSA; pH 7.4]. Cells were loaded in the dark with fura 2-AM (final concentration 5 M) for 30 min, followed by three buffer washes. Coverslips were inserted into a microcuvette containing 500 l buffer at 37°C. The excitation signals (340/380 nm) were determined using a fluorimeter designed to monitor fura 2 fluorescence (JASCO CAF-100 Ca 2ϩ Analyzer, Japan Spectroscopic; Tokyo, Japan). Details of calibration and determination of basal and agonist-evoked increases in [Ca 2ϩ ]i levels have been described previously (14, 34) . The concentration-peak [Ca 2ϩ ]i response (CR) curves to each agonist [ANG II, arginine vasopressin (AVP), endothelin (ET-1), and LTC4 or LTD4] were evaluated using fresh coverslips of fura 2-loaded cells for each challenge. CR determinations for LTC4 and LTD4 were performed in the buffer medium devoid of BSA. The CR determinations to agonists were also performed in the presence of optimal concentration(s) of the 5-LO inhibitor AA-861 [either 10 or 30 M (29, 30, 33)], the CysLT1 antagonist MK-571 [100 nM (16, 26, 29, 30) ], the dual CysLT1/CysLT2 antagonist BAY-u9773 [100 nM (8) ], the AT1-selective antagonist losartan [1 M (3, 12, 27, 28) ], the AT2-selective antagonist PD-123319 [1 M (3, 12, 7, 27, 28, 32) ], and the cell-permeant Ins(1,4,5)P3 blocker 2-aminoethoxydiphenyl borate [2-APB; 50 M (18)]. The concentrations of all these agents were carefully chosen to ensure their selectivity of inhibition/blockade as validated by previous reports. Each agent was maintained in the cuvette for 3 min before the agonist challenge. In select experiments, the fura 2-loaded cells on coverslips were washed and placed in Ca 2ϩ -free buffer with 1 mM EGTA (pH 7.4) in the cuvette for 15 min before the agonist challenge and fluorescence measurements.
Single cell fura 2 imaging. NRC grown on glass coverslips (Delta T Dish 0.15 nm, Bioptechs; Butler, PA) were maintained in DMEM for 3 days and changed to serum-free medium for 24 h. The cells were washed in Krebs-HEPES buffer and subjected to fura 2 loading and washing. The dish was mounted on the stage of an inverted Olympus I ϫ70 epifluorescence microscope fitted with the specification of UApo20ϫ/340.5 objective that has the capability to monitor the apochromat-reflected light fluorescence of fura 2. The fura 2 fluorescence images were acquired using a fast monochromatic integral 125-W xenon light source (SpectraMaster Monochromator, Life Science Resources, Perkin Elmer; Gaithersburg, MD) with a shutter speed for monitoring alternate 340-and 380-nm excitation signals every 200 ms. Ratiometric signals at 340/380 nm were acquired at a rate of 3 images/s. The emission signal at 510 nm was collected using a charge-coupled device camera (Astrocam; Cambridge, UK). The digitized signals were stored and processed using UltraVIEW Imaging System software (Wallac Imaging, Perkin Elmer). ANG II (50 nM) was added to the coverslips after images were acquired for the first 30 s to determine basal fura 2 fluorescence. Interacting agents were added to fura 2-loaded cells for 3 min before imaging. The respective Ca 2ϩ -saturated and Ca 2ϩ -free 340-to-380-nm fluorescence ratio values were determined using the Ca 2ϩ ionophore bromo-A-23187 (50 M) and then by quenching with 50 l of Tris (50 mM)-EGTA (100 mM) solution (pH 8.5) at the end of each experiment. Once these values were entered, the software program employed provided the absolute [Ca 2ϩ ]i values for each cell using the Grynckiewicz equation.
Total CysLT measurement. NRC grown on six-well culture plates for 3 days (ϳ0.3-0.5 ϫ 10 6 cells/well) were maintained for the last 24 h in 2 ml of medium devoid of serum. The medium was replaced with Krebs-HEPES buffer before stimulation with ANG II (100 nM) for varying time intervals (from 5 to 360 s). CR determinations for ANG II (100 pM-1 M)-evoked increases, AVP (100 pM-1 M)-evoked increases, and ET-1 (100 pM-1 M)-evoked increases in CysLT levels were determined 1 min after the addition of the respective agonist(s). All these assays were performed in duplicate. The responses to ANG II were also determined in the presence of AA-861 (10 M), losartan (1 M), or PD-123319 (1 M). A 450-l aliquot of culture medium was stored in siliconized tubes at Ϫ80°C. Total CysLT levels were determined within 10 days of storage by enzyme immunoassay following the protocol provided by Cayman Chemicals (Ann Arbor, MI). Total CysLT levels were assayed spectrophotometrically (405 nm for measurement of acetylcholinesterase activity) as outlined in the kit using a Anthos HT1 96-well microplate reader (Anthos Labtec Instruments; Salzburg, Austria). The lowest detection limit was 4.0 pg/ml, and the 50% (B/B0) ratio was 40 pg/ml. The intra-and interassay coefficients of variation were 7.3 Ϯ 2.5% and 5.8 Ϯ 2.9%, respectively. Cells were counted, and the data were normalized to express the values as CysLT per milliliter per million cells.
Materials and supplies. Fura 2-AM and pluronic acid F-127 were from Molecular Probes (Eugene, OR). Culture media, DMEM, serum, and trypsin were from GIBCO-BRL (Life Technologies; Grand Island, NY). AVP, ANG II, and ET-1 were from Bachem (Torrance, CA). Bromodeoxyuridine, AA-861, PD-123319, 2-APB, and analytic grade salts for the preparation of Krebs buffer were purchased from Sigma Chemical (Oakville, Ontario, Canada). BAY-u9773 was obtained from BioMol Research Laboratories (Plymouth Meeting, PA). MK-571 and losartan were provided by Merck-Frosst Canada. LTC4, LTD4, and enzyme immunoassay kits for the estimation of CysLTs were obtained from Cayman Chemicals.
Statistical analysis. Experimental values are reported as means Ϯ SE of a minimum of five separate experiments performed on different days using different batches of NRC. Comparison of mean values was performed by ANOVA (Super ANOVA software). Simultaneous multiple comparisons were assessed using Scheffé's F-test, and the concentration of agonist required to produce 50% of the maximal response (EC 50) and the maximal increase in [Ca 2ϩ ]i (Emax) values attained for each agonist were derived from log CR curves.
RESULTS
The basal [Ca 2ϩ ] i levels in normal Ca 2ϩ buffer were 90 Ϯ 12 nM in multiple cells (n ϭ 54) and 121 Ϯ 18 nM in single cells (n ϭ 23), and the differences in resting levels observed by both methods were not significant. None of the interacting agents (AA-861, MK-571, BAYu9773, 2-APB, losartan, or PD-123319) affected the basal fura 2 fluorescence ratio. A representative tracing of ANG II-evoked increases in the fura 2 fluorescence ratio performed on the same day in the presence or absence of either AA-861 (10 M) or MK-571 (100 nM) is shown in Fig. 1 . The addition of ANG II led to a rapid concentration-dependent increase in the ratio of fura 2 fluorescence in multiple cells, with maximal increases observed between 30 s and 1 min; at 2 min after stimulation, the fluorescence ratio decreased to a steady state above the basal level. The CR curves to ANG II determined in either normal Ca 2ϩ (1.8 mM) or Ca 2ϩ -free buffer is shown in Fig. 2 . The addition of AA-861 (10 M) or MK-571 (100 nM) led to a significant reduction in ANG II-evoked increases in peak [Ca 2ϩ ] i values (P Ͻ 0.01) in both normal and Ca 2ϩ -free buffer. Moreover, the addition of AA-861 or MK-571 did not affect either the time to attain the peak response or the time for reduction in peak Ca 2ϩ to steady-state levels for varying concentrations of ANG II (Fig. 1) . The effect of blockade on ANG II responses was similar when AA-861 was increased to 30 M. Although the E max values for ANG II were relatively lower in Ca 2ϩ -free medium, both AA-861 and MK-571 evoked a similar degree of blockade (percent reduction in E max ) of ANG II responses (Fig. 2, right) . These data suggest that both AA-861 and MK-571 decrease the E max with no change in EC 50 values for ANG II-evoked peak [Ca 2ϩ ] i responses (Table 1) . In contrast, a high concen- buffer. AA-861 or MK-571 was maintained in the cuvette in the indicated buffer for a period of 3 min before the addition of the agonist. The Emax of ANG II or AVP was attained at 1 M, whereas the Emax of ET-1 was reached at 100 nM. Note that stimulation with either AVP or ET-1 was not performed in Ca 2ϩ -free buffer because no significant changes in the EC50 and Emax values were noted in normal Ca 2ϩ buffer. * P Ͻ 0.01 compared with the respective control group. tration of either AA-861 (30 M) or MK-571 (100 nM) failed to affect the CR curves to AVP or ET-1 (Table 1) .
A representative tracing of ANG II-, LTD 4 -, and LTC 4 -evoked [Ca 2ϩ ] i responses is shown in Fig. 3 . Both LTC 4 and LTD 4 evoked rapid increases in peak [Ca 2ϩ ] i levels (E max : LTD 4 ϾϾ LTC 4 ) with a similar time course but much lower E max compared with ANG II. The peak responses were attained at 40, 43, and 47 s after the addition of ANG II, LTD 4 , and LTC 4 , respectively. The plateau phase that sustained at levels slightly above their respective baseline values were reached between 120 and 180 s after the addition of respective agonist(s). There were no significant differences between them (Fig. 3) . The inclusion of MK-571 significantly attenuated the E max and increased the EC 50 value for LTD 4 , but it failed to evoke a significant reduction in the weak [Ca 2ϩ ] i signals evoked by LTC 4 . On the contrary, the inclusion of a nonselective CysLT antagonist, BAY-u9773, completely blocked the [Ca 2ϩ ] i responses to both LTD 4 and LTC 4 (Fig. 4) . The analysis of data obtained from several CR curves is summarized in Table 2 . The Ins(1,4,5)P 3 blocker 2-APB and the AT 1 -selective antagonist losartan significantly attenuated the responses to ANG II, whereas PD-123319 had no effect on either basal or ANG II-evoked peak [Ca 2ϩ ] i responses (Fig. 5, left) . 2-APB also attenuated the maximal [Ca 2ϩ ] i responses, with a significant reduction in E max values for LTD 4 (Fig. 5, right) .
Single cell Ca 2ϩ imaging studies revealed qualitatively similar results. A typical experiment performed with ANG II stimulation (50 nM) on three different coverslips loaded with fura 2 on the same day using the same batch of cardiomyocytes is shown in Fig. 6 . Basal fluorescence levels before stimulation are shown in The basal CysLT level in the culture medium was 9.7 Ϯ 1.9 pg ⅐ ml Ϫ1 ⅐ 10 6 cells Ϫ1 . The addition of ANG II led to a rapid, time-dependent increase in the CysLT Fig. 3 . Representative experiment of ANG II-and leukotriene D4 (LTD4)-and C4 (LTC4)-evoked changes in the ratio of fura 2 fluoresence (340/380 nm) in NRC. Primary cultures of NRC grown on coverslips and loaded with fura 2 were stimulated with either ANG II (100 nM), LTD4 (100 nM), or LTC4 (100 nM). These agents were added to the cuvette in Krebs buffer (pH 7.4) containing normal Ca 2ϩ (1.8 mM) at 37°C. Note that each coverslip containing fura 2-loaded NRC was stimulated only once with a single agonist. Values are means Ϯ SE; n ϭ 6 experiments. LTD4 and LTC4, leukotriene D4 (10 pM-10 M) and C4 (10 pM-10 M), respectively. The basal level of [Ca 2ϩ ]i in the absence of either LTD4 or LTC4 stimulation was 90 Ϯ 12 nM. MK-571 or BAY-u9773 was added 3 min before the addition of agonist to the cuvette. * P Ͻ 0.05 and † P Ͻ 0.01 compared with the respective control group. level, reaching a maximum (19.8 Ϯ 2.6 pg ⅐ ml Ϫ1 ⅐ 10 6 cells Ϫ1 ) at 1 min, remaining at the same level until 5 min, and gradually decreasing thereafter. However, the increases in CysLT levels were significantly higher (15.7 Ϯ 1.8 pg ⅐ ml Ϫ1 ⅐ 10 6 cells Ϫ1 ) even at 30 s after the addition of ANG II (Fig. 7, left) . The CR determinations for CysLT generation revealed that the ANG II effect was also concentration dependent. The E max for ANG II (100 nM)-evoked CysLT release was twofold higher than the basal level. In contrast to ANG II, the addition of either ET-1 (100 nM) or AVP (100 nM) failed to evoke a significant increase in CysLT production. The inclusion of losartan or AA-861 led to a significant reduction in ANG II-evoked total CysLT release into the culture medium, whereas the addition of PD-123319 failed to affect either the basal or ANG II-evoked increases in CysLT production (Fig. 7, right) . CysLT generation was significantly higher at 30 s, and the peak [Ca 2ϩ ] i increase was reached at 40 s after the addition of ANG II (100 nM), suggesting that the increased CysLT generation evoked by ANG II may contribute to an elevation in [Ca 2ϩ ] i (Figs. 3 and 7) .
DISCUSSION
The present study provides several new observations: First, the 5-LO-derived metabolites of AA, CysLT, augment [Ca 2ϩ ] i responses to ANG II in NRC. Second, the inclusion of the 5-LO inhibitor AA-861 (10 M) led to significant attenuation of ANG II-evoked increases, but not ET-1-and AVP-evoked increases, in peak [Ca 2ϩ ] i levels and CysLT release into the culture medium. Third, ANG II-evoked increases in [Ca 2ϩ ] i levels and CysLT release in NRC are mediated by AT 1 2 , and that ANG II-induced alkalinization was sensitive to blockade by AT 2 -selective but not AT 1 -selective antagonists. Others have suggested that AT 1 -mediated hypertrophy by ANG II could be opposed by AT 2 -mediated antigrowth events in NRC (3) . In contrast to these reports, detailed characterization of AT 1 -and AT 2 -specific binding sites and receptor expression studies have revealed the presence of only a single class of AT 1 -specific binding sites on NRC (32) . Several studies by others have also established that both the increases in [Ca 2ϩ ] i and all phospholipid second messenger systems evoked by ANG II in NRC are indeed mediated solely by the activation of the AT 1 subtype and not the AT 2 subtype (12, 27, 32) . Others have established that ANG II can also activate phospholipase A 2 and D, leading to an elevation in AAderived metabolites (6, 15, 19, 22, 24, 31, 36) . The present study demonstrates that ANG II-evoked increases in CysLT and [Ca 2ϩ ] i levels were abolished by losartan but not by PD-123319. Therefore, AT 1 receptor activation and the resultant PLC/Ins(1,4,5)P 3 -mediated [Ca 2ϩ ] i responses may also be partly mediated by AA-derived CysLT production in NRC. The focus of the present study was to examine the involvement of CysLT in the ANG II-mediated elevation in peak [Ca 2ϩ ] i responses. ANG II-CysLT interaction. Previous studies have shown that ANG II-evoked vascular hypertrophy may be mediated by noncycloxygenase-derived AA metabolites (6, 22, 36) . The 5-LO inhibitor AA-861 or the CysLT 1 antagonist MK-571 reduced the vasoconstrictor responses to ANG II, suggesting that CysLT generation and the subsequent CysLT 1 receptor activation may mediate vasoconstriction to ANG II (29, 30) . Therefore, it was important to provide direct evidence at the level of signal transduction for a link among ANG II, AT 1 receptor activation, CysLT generation, and CysLT receptor-mediated alterations in [Ca 2ϩ ] i levels. It is well known that cell surface receptors for ET-1 are several orders of magnitude higher than the receptors for ANG II in NRC (3). Previously, we have (1.8 mM) buffer in either the absence (control; E) or the presence of the angiotensin type 1 (AT1) receptor antagonist losartan (1 M; F) , or the AT2 receptor antagonist PD-123319 (1 M; ), or the inositol (1,4,5)-trisphosphate antagonist 2-APB (50 M; OE). CR curve determination for LTD4 (right) was restricted to studies in the presence or absence of 2-APB (50 M) alone because losartan and PD-123319 failed to alter the control CR curve to LTD4 in preliminary experiments. Each curve was determined six times using different batches of NRC. *P Ͻ 0.05 and **P Ͻ 0.01 compared with losartan-and 2-APB-treated cells.
shown that ANG II evoked much greater increases in [Ca 2ϩ ] i than both AVP and ET-1 in NRC (34, 35) . These data suggest that additional mechanisms and signal transduction events likely account for the much greater increases in the [Ca 2ϩ ] i response to ANG II. The present data confirm that ANG II increased CysLT generation via AT 1 receptor activation, which in turn augments the [Ca 2ϩ ] i response to ANG II. In contrast, AVP-and ET-1-evoked increases in [Ca 2ϩ ] i levels were not reduced by the inclusion of either AA-861 or MK-571. Moreover, both ET-1 and AVP failed to promote CysLT production, suggesting that only ANG II promotes CysLT production via AT 1 receptor activation. This is consistent with the view that ANG II is a pleiotropic agonist that recruits multiple signaling pathways to account for its potential role in the regulation of cardiovascular function (31) . Previously, others have confirmed that ANG II-evoked increases in [Ca 2ϩ ] i might play a more important role than protein kinase C activation in hypertrophic responses to ANG II in NRC (28) . The present study demonstrates the consistency in the time course response for CysLT generation and the subsequent Ca 2ϩ increase, suggesting that CysLT generation evoked by ANG II may serve as an additional amplifier pathway in sustaining direct AT 1 -mediated Ca 2ϩ mobilization in NRC. Several studies in the past have established that ANG IIand AVP-evoked elevations in [Ca 2ϩ ] i in NRC stemmed predominantly from the release of Ca 2ϩ from the intracellular stores and that removal of extracellular Ca 2ϩ led to only a partial reduction in the peak increases in [Ca 2ϩ ] i evoked by ANG II and AVP (7, 12, 14, 32 ] i response to ANG II or AVP (12, 14) . Therefore, the ANG II-evoked responses noted in Ca 2ϩ -free medium or the significant attenuation of [Ca 2ϩ ] i responses to ANG II seen in the presence of 2-APB are consistent with observations reported earlier. Thus, besides providing a possible explanation for the higher E max to ANG II, the present study suggests for the first time that CysLT may play a role in ANG II-evoked contractility and/or hypertrophy in cardiomyocytes.
CysLT and Ca 2ϩ signaling. It is important to demonstrate that CysLT contributes to Ca 2ϩ mobilization in NRC. There are no studies suggesting the presence of CysLT receptors in NRC. In human detrusor smooth muscle cells, it was reported that elevation in [Ca 2ϩ ] i levels evoked by LTD 4 were almost exclusively due to mobilization from intracellular Ca 2ϩ stores (4) . In other target cells, the LTD 4 -evoked Ca 2ϩ response was dependent on the release of Ca 2ϩ from intracellular stores and enhanced Ca 2ϩ influx (20, 23) . The present study demonstrates that both ANG II-and CysLTevoked increases in [Ca 2ϩ ] i levels were significantly attenuated by 2-APB. In addition, both AA-861 and MK-571 caused a similar degree of blockade of the ANG II response in normal as well as Ca 2ϩ -free buffer. Thus this is the first report to characterize CysLTevoked increases in [Ca 2ϩ ] i that may be mainly due to the release of Ca 2ϩ from Ins(1,4,5)P 3 -sensitive intracellular SR Ca 2ϩ pools in NRC. Human CysLT 1 and CysLT 2 receptors have been cloned and characterized only in recent years (8, 16) . Several recent studies have proposed the presence of CysLT 1 and CysLT 2 transcripts in cardiac tissues (8, 10, 16, 21 (1, 8, 16) . Moreover, zafirlukast-resistant contractile responses to LTC 4 were observed in the guinea pig trachea when LTC 4 metabolism to LTD 4 was prevented (1). In CysLT 2 -expressing clones, such as CHO-7A, CHO-8B3, and PC12 cells, both LTC 4 and LTD 4 exhibited dose-dependent increases in [Ca 2ϩ ] i levels that were sensitive to blockade by BAY-u9773 (21) . Peritoneal macrophages (which express both CysLT 1 and CysLT 2 receptors) responded substantially to 1 M LTD 4 and only slightly to 1 M LTC 4 (17) . All these studies, together with our present data using NRC, support the notion that LTD 4 Although several studies have suggested that CysLT evoke a negative inotropic effect, this has been attributed to profound coronary vasoconstriction mediated by CysLT 2 receptors located on coronary arteries (10). Indeed, both LTD 4 and LTC 4 at low concentrations have been shown to exert a positive inotropic effect on the rat myocardium, and ANG II infusion has been shown to enhance leukotriene A 4 hydrolase activity in the rat heart (9, 11). These findings support our observation of elevated [Ca 2ϩ ] i levels evoked by CysLT in NRC. In fact, the elevation in the [Ca 2ϩ ] i level has been suggested to play a more critical role than protein kinase C activation toward hypertrophy evoked by ANG II in NRC (27, 28) . Taken together with our new findings, these data provide the impetus for a more detailed characterization of the interactions among ANG II, CysLT generation, and CysLT receptor-mediated increases in Ca 2ϩ mobilization and their relative roles and contribution to cardiac hypertrophy.
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